Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies BioTime, Inc.)
Reporting Period: Quarterly period ended March 31, 1997.
Status: Development stage company engaged in research and development of synthetic plasma expanders, blood volume substitutes, and organ preservation solutions. The company has not generated significant operating revenues and relies on equity financing and licensing agreements.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1997 | Nine Months Ended Mar 31, 1997 | Cumulative from Inception |
|---|---|---|---|
| Total Revenues | $46,628 | $86,593 | $815,925 |
| Net Loss | $(520,282) | $(1,993,125) | $(10,057,596) |
| Net Loss Per Share | $(0.17) | $(0.69) | $(4.89) |
| Cash and Cash Equivalents | $7,345,433 (as of Mar 31, 1997) | ||
| Total Assets | |||
| Total Liabilities | $101,871 (Accounts Payable) | ||
| Shareholders' Equity | $7,642,141 |
Revenue Composition: Revenues are primarily derived from interest income ($762,060 cumulative) rather than product sales ($53,865 cumulative).
Material Changes vs. Prior Period
- Liquidity Increase: Cash and cash equivalents increased from $2,443,121 (June 30, 1996) to $7,345,433 (March 31, 1997). This was driven by a subscription rights offering completed on February 5, 1997, which raised $5,662,180 net of offering costs.
- Expense Growth: Research and development (R&D) expenses increased to $392,237 for the quarter (from $253,911 in the prior year quarter) and $1,310,062 for the nine-month period (from $793,769). This increase is attributed to ongoing Phase III clinical trials for Hextend(R) and the initiation of a second study site.
- General and Administrative (G&A): G&A expenses decreased slightly for the quarter ($174,673 vs. $188,515) but increased for the nine-month period ($769,656 vs. $528,519), largely due to amortization of capitalized service costs related to financial advisor warrants.
Guidance, Outlook, and Risks
- Strategic Partnership: On April 23, 1997 (subsequent to period end), BioTime entered an Exclusive License Agreement with Abbott Laboratories. Abbott received rights to manufacture and sell Hextend(R) in the U.S. and Canada (excluding hypothermic surgery). BioTime received $1,000,000 upfront and is eligible for up to $40,000,000 in additional license fees and royalties (5% to 36% of net sales).
- Outlook: Management expects losses to continue for the foreseeable future as the company funds clinical trials and product development. Future profitability depends on regulatory approvals (FDA) and successful commercialization.
- Risks: Key risks include the outcome of clinical trials, ability to obtain FDA approval, competition, and the need for additional financing to complete development activities. The company notes that the unavailability of financing could force a curtailment of operations.
Investor Verification Checklist
- Clinical Trial Status: Verify the progress and results of the Phase III clinical trials for Hextend(R) currently underway at Duke University and Mt. Sinai.
- Abbott Agreement Milestones: Confirm the specific milestones required to trigger the $400,000 payment due in the quarter ending June 30, 1997, and subsequent payments.
- Cash Burn Rate: Assess whether the current cash balance of ~$7.3 million is sufficient to fund operations until the next anticipated revenue stream or financing event.
- Regulatory Path: Monitor the timeline for the New Drug Application (NDA) filing for Hextend(R) and FDA review status.
- Dilution: Review the impact of outstanding options (245,000 shares) and warrants (including those issued to financial advisors) on future share count and earnings per share.